Overview

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This is a single center, single arm, phase II, prospective study to evaluate the safety and effectiveness of HAIC combined with TAE plus an ICI and an TKI in adult patients (aged ≥18 years) with unresectable intrahepatic cholangiocarcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Qilu Hospital of Shandong University

Collaborator:

BeiGene

Treatments:

surufatinib
tislelizumab